Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial

Background and Objective. The aim of this study was to compare the effect of autologous bone marrow-derived chondrocytes (ABMDCs) with pharmacological management of osteoarthritis of knee (OAK) and assess the benefit of the two in the improvement of pain relief, functional betterment, and quality of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mir Sadat-Ali, Abdallah S. AlOmran, Sulaiman A. AlMousa, Hasan N. AlSayed, Khalid W. AlTabash, Mohammed Q. Azam, Tarek M. Hegazi, Sadananda Acharya
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Orthopedic surgery RD701-811
Acceso en línea:	https://doaj.org/article/96c435dec75649b7b607cc235c8bf402
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:96c435dec75649b7b607cc235c8bf402
record_format	dspace
spelling	oai:doaj.org-article:96c435dec75649b7b607cc235c8bf4022021-11-29T00:55:50ZAutologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial2090-347210.1155/2021/2146722https://doaj.org/article/96c435dec75649b7b607cc235c8bf4022021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/2146722https://doaj.org/toc/2090-3472Background and Objective. The aim of this study was to compare the effect of autologous bone marrow-derived chondrocytes (ABMDCs) with pharmacological management of osteoarthritis of knee (OAK) and assess the benefit of the two in the improvement of pain relief, functional betterment, and quality of life (QOL). Patients and Methods. A prospective, randomized study was undertaken in patients with OAK grades II and III of Kellgren–Lawrence grading (KLG) in two groups. Group I had 5 million of intra-articular ABMDC in the affected joint, and Group II continued the nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy as needed. Before the treatment, patients were meticulously examined and data were entered for age, sex, Body Mass Index (BMI), Visual Analogue Scale (VAS), Modified Knee Society Score-Short Form (MKSSSF), and QOL. Patients were followed up for 3, 12, and 24 months to assess efficacy, safety, and tolerability. To assess the cartilage regeneration of the damaged cartilage, magnetic resonance imaging (MRI) was used. Results. There were a total of 60 patients who were followed up. Three patients in Group II were removed from the analysis as they underwent total knee arthroplasty (TKA). A notably significant improvement was noticed in the ABMDC group on all scores of VAS and MKSSSF with P<0.0001. The control group continued to be dissatisfied with the treatment they were taking. Conclusions. This study reveals that a single injection of 5 million of ABMDC was efficient in reducing the symptoms, improving the functional score and betterment of QOL.Mir Sadat-AliAbdallah S. AlOmranSulaiman A. AlMousaHasan N. AlSayedKhalid W. AlTabashMohammed Q. AzamTarek M. HegaziSadananda AcharyaHindawi LimitedarticleOrthopedic surgeryRD701-811ENAdvances in Orthopedics, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Orthopedic surgery RD701-811
spellingShingle	Orthopedic surgery RD701-811 Mir Sadat-Ali Abdallah S. AlOmran Sulaiman A. AlMousa Hasan N. AlSayed Khalid W. AlTabash Mohammed Q. Azam Tarek M. Hegazi Sadananda Acharya Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial
description	Background and Objective. The aim of this study was to compare the effect of autologous bone marrow-derived chondrocytes (ABMDCs) with pharmacological management of osteoarthritis of knee (OAK) and assess the benefit of the two in the improvement of pain relief, functional betterment, and quality of life (QOL). Patients and Methods. A prospective, randomized study was undertaken in patients with OAK grades II and III of Kellgren–Lawrence grading (KLG) in two groups. Group I had 5 million of intra-articular ABMDC in the affected joint, and Group II continued the nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy as needed. Before the treatment, patients were meticulously examined and data were entered for age, sex, Body Mass Index (BMI), Visual Analogue Scale (VAS), Modified Knee Society Score-Short Form (MKSSSF), and QOL. Patients were followed up for 3, 12, and 24 months to assess efficacy, safety, and tolerability. To assess the cartilage regeneration of the damaged cartilage, magnetic resonance imaging (MRI) was used. Results. There were a total of 60 patients who were followed up. Three patients in Group II were removed from the analysis as they underwent total knee arthroplasty (TKA). A notably significant improvement was noticed in the ABMDC group on all scores of VAS and MKSSSF with P<0.0001. The control group continued to be dissatisfied with the treatment they were taking. Conclusions. This study reveals that a single injection of 5 million of ABMDC was efficient in reducing the symptoms, improving the functional score and betterment of QOL.
format	article
author	Mir Sadat-Ali Abdallah S. AlOmran Sulaiman A. AlMousa Hasan N. AlSayed Khalid W. AlTabash Mohammed Q. Azam Tarek M. Hegazi Sadananda Acharya
author_facet	Mir Sadat-Ali Abdallah S. AlOmran Sulaiman A. AlMousa Hasan N. AlSayed Khalid W. AlTabash Mohammed Q. Azam Tarek M. Hegazi Sadananda Acharya
author_sort	Mir Sadat-Ali
title	Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial
title_short	Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial
title_full	Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial
title_fullStr	Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial
title_full_unstemmed	Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial
title_sort	autologous bone marrow-derived chondrocytes for patients with knee osteoarthritis: a randomized controlled trial
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/96c435dec75649b7b607cc235c8bf402
work_keys_str_mv	AT mirsadatali autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial AT abdallahsalomran autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial AT sulaimanaalmousa autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial AT hasannalsayed autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial AT khalidwaltabash autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial AT mohammedqazam autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial AT tarekmhegazi autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial AT sadanandaacharya autologousbonemarrowderivedchondrocytesforpatientswithkneeosteoarthritisarandomizedcontrolledtrial
_version_	1718407785132064768

Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial

Ejemplares similares